{"id":"sofosbuvir-velpatasvir-voxilaprevir","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Asthenia"}]},"_chembl":{"chemblId":"CHEMBL3545062","moleculeType":"Small molecule","molecularWeight":"883.02"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase. Velpatasvir inhibits the NS5A protein, which is essential for viral replication and assembly. Voxilaprevir inhibits the NS3/4A serine protease. Together, these three agents target different steps of the HCV lifecycle, providing a pangenotypic, direct-acting antiviral regimen with high barrier to resistance.","oneSentence":"This combination inhibits three key hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:41.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotypes 1-6), including treatment-experienced patients with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT03949764","phase":"PHASE4","title":"The Kentucky Viral Hepatitis Treatment Study","status":"COMPLETED","sponsor":"Jennifer Havens","startDate":"2019-09-23","conditions":"Hepatitis C, Opioid-Related Disorders, Injection Drug Use","enrollment":374},{"nctId":"NCT07098481","phase":"PHASE4","title":"Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-09-01","conditions":"Hepatitis C Virus Infection","enrollment":576},{"nctId":"NCT06829966","phase":"","title":"Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-05-13","conditions":"Intestinal Microbiota Between Different Groups","enrollment":30},{"nctId":"NCT05717400","phase":"PHASE4","title":"Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-03-17","conditions":"Liver Cancer","enrollment":2},{"nctId":"NCT06180590","phase":"","title":"The Efficacy of Vosevi in Treating DAA-experienced Patients","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Guangzhou Medical University","startDate":"2023-02-28","conditions":"Chronic Hepatitis C, Medication Reaction","enrollment":200},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT06010524","phase":"","title":"A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX","status":"UNKNOWN","sponsor":"Cerrahpasa Medical Faculty Foundation","startDate":"2023-02-01","conditions":"Hepatitis C","enrollment":450},{"nctId":"NCT03823911","phase":"PHASE4","title":"Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-11-18","conditions":"Cardiovascular Diseases, Hepatitis C, Hiv","enrollment":87},{"nctId":"NCT02510300","phase":"","title":"A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-10-21","conditions":"Hepatitis C Virus Infection","enrollment":461},{"nctId":"NCT04695769","phase":"PHASE4","title":"Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-11-21","conditions":"Chronic Hepatitis C","enrollment":281},{"nctId":"NCT05467826","phase":"PHASE4","title":"Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-09-01","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT02745535","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2016-05","conditions":"Chronic Hepatitis C","enrollment":77},{"nctId":"NCT02938013","phase":"PHASE4","title":"deLIVER: Direct Acting Antiviral Effects on the Liver","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-01","conditions":"HCV Coinfection, Liver Disease, HIV","enrollment":15},{"nctId":"NCT05092074","phase":"","title":"Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-10-01","conditions":"Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment","enrollment":100},{"nctId":"NCT04211909","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-01-03","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT03619837","phase":"PHASE4","title":"Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-07-15","conditions":"Hepatitis C, Transplantation Disease Transmission","enrollment":122},{"nctId":"NCT04662138","phase":"","title":"Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2020-08-24","conditions":"Hepatitis C, Relapse, Antivirals","enrollment":100},{"nctId":"NCT03820258","phase":"PHASE2","title":"Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-01-28","conditions":"Hepatitis C Virus Infection","enrollment":21},{"nctId":"NCT02185794","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-06-13","conditions":"Hepatitis C Virus Infection","enrollment":101},{"nctId":"NCT02533427","phase":"PHASE1","title":"Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-10-29","conditions":"HCV Infection","enrollment":15},{"nctId":"NCT02378935","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-17","conditions":"Hepatitis C Virus Infection","enrollment":205},{"nctId":"NCT02378961","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-16","conditions":"Hepatitis C Virus Infection","enrollment":128},{"nctId":"NCT03888729","phase":"PHASE4","title":"Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)","status":"UNKNOWN","sponsor":"Partners in Health","startDate":"2019-08-26","conditions":"Hepatitis C, Chronic","enrollment":100},{"nctId":"NCT03118843","phase":"PHASE3","title":"Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-04-25","conditions":"Hepatitis C Virus Infection","enrollment":31},{"nctId":"NCT02607735","phase":"PHASE3","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"Hepatitis C","enrollment":416},{"nctId":"NCT02639247","phase":"PHASE3","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-23","conditions":"Hepatitis C Virus Infection","enrollment":333},{"nctId":"NCT02607800","phase":"PHASE3","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-16","conditions":"Hepatitis C","enrollment":943},{"nctId":"NCT02639338","phase":"PHASE3","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-23","conditions":"Hepatitis C Virus Infection","enrollment":220},{"nctId":"NCT02536313","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-07-29","conditions":"Hepatitis C Virus Infection","enrollment":49},{"nctId":"NCT03164902","phase":"NA","title":"Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence","status":"UNKNOWN","sponsor":"Proteus Digital Health, Inc.","startDate":"2017-07-21","conditions":"Hepatitis C, Chronic, Nonadherence, Patient","enrollment":253},{"nctId":"NCT02202980","phase":"PHASE2","title":"Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08-04","conditions":"Chronic Hepatitis C","enrollment":273}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":110,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vosevi","SOF/VEL/VOX","GS-7977/GS-5816/GS-9857"],"phase":"marketed","status":"active","brandName":"Sofosbuvir/Velpatasvir/Voxilaprevir","genericName":"Sofosbuvir/Velpatasvir/Voxilaprevir","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits three key hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), including treatment-experienced patients with compensated cirrhosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}